Yesim Eralp

Prof. Dr. Yesim Eralp


Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 April 2004 in Breast Cancer Research
Verified
Journal Article
Open access
YEYesim Eralp
Yesim Eralp
XWXiaoyan Wang
Xiaoyan Wang
JWJian-Ping Wang
Jian-Ping Wang
MMMaureen F Maughan
Maureen F Maughan
JPJohn M Polo
John M Polo
LLLawrence B Lachman
Lawrence B Lachman
The purpose of the present study was to determine whether cytotoxic chemotherapeutic agents administered prior to immunotherapy with gene vaccines could augment the efficacy of the vaccines. Mice were injected in the mammary fat pad with an aggressive breast tumor cell line that expresses HER2/neu. The mice were treated 3 days later with a noncurative dose of either doxorubicin or paclitaxel, and the following day with a gene vaccine to HER2/neu. Two more doses of vaccine were given 14 days apart. Two types of gene vaccines were tested: a plasmid vaccine encoding a self-replicating RNA (replicon) of Sindbis virus (SINCP), in which the viral structural proteins were replaced by the gene for neu; and a viral replicon particle derived from an attenuated strain of Venezuelan equine encephalitis virus, containing a replicon RNA in which the Venezuelan equine encephalitis virus structural proteins were replaced by the gene for neu. Neither vaccination alone nor chemotherapy alone significantly reduced the growth of the mammary carcinoma. In contrast, chemotherapy followed by vaccination reduced tumor growth by a small, but significant amount. Antigen-specific CD8+ T lymphocytes were induced by the combined treatment, indicating that the control of tumor growth was most probably due to an immunological mechanism. The results demonstrated that doxorubicin and paclitaxel, commonly used chemotherapeutic agents for the treatment of breast cancer, when used at immunomodulating doses augmented the antitumor efficacy of gene vaccines directed against HER2/neu. The combination of chemotherapeutic agents plus vaccine immunotherapy may induce a tumor-specific immune response that could be beneficial for the adjuvant treatment of patients with minimal residual disease. The regimen warrants further evaluation in a clinical setting.

15 November 2007 in Annals of Oncology
Verified
Journal Article
Open access
PDF file
YEYesim Eralp
Yesim Eralp
DDD. Derin
D. Derin
YOY. Ozluk
Y. Ozluk
EYE. Yavuz
E. Yavuz
NGN. Guney
N. Guney
ETE. Topuz
E. Topuz
Background: Triple-negative breast cancer is estimated to account for 15%–20% of all patients with breast cancer and is considered as a prognostically unfavorable subset. The aim of this study is to evaluate the prognostic impact of various molecular factors in patients with triple-negative breast cancer. Patients and methods: Tumor specimens from 109 patients with receptor-negative (estrogen receptor and progesterone receptor) breast cancer were analyzed for mitogen-activated protein kinase (MAPK), epidermal growth factor receptor (EGFR) and phosphoinositol-3-kinase (PI3K) expression by immunohistochemistry. The prognostic significance of these molecular factors, in addition to various prognostic variables, was investigated. Results: Fifteen (13.8%), 38 (34.9%) and 33 patients (30.3%) had positive staining for EGFR, MAPK and PI3K, respectively. MAPK was associated with anthracycline resistance (P = 0.008) and lower MAPK score was significantly associated with shorter disease-free survival (P = 0.029). Survival following relapse was significantly worse for those with a higher MAPK score (P = 0.03). Conclusion: MAPK is a significant prognostic and predictive factor in patients with triple-negative breast cancer. Furthermore, the level of staining among those with a positive MAPK expression may play a prognostic role at different stages of relapse. Further translational research is required to elucidate molecular mechanisms of tumor proliferation in this subset of patients.

1 January 2008 in Gynecologic Oncology
Verified
Journal Article
Closed access
YEYesim Eralp
Yesim Eralp
PSPinar Saip
Pinar Saip
ZAZeki Aydin
Zeki Aydin
SBSinan Berkman
Sinan Berkman
ETErkan Topuz
Erkan Topuz

5 August 2022 in Vaccines
Verified
Journal Article
Open access
PDF file
YEYesim Eralp
Yesim Eralp
MRNA-based therapeutics pose as promising treatment strategies for cancer immunotherapy. Improvements in materials and technology of delivery systems have helped to overcome major obstacles in generating a sufficient immune response required to fight a specific type of cancer. Several in vivo models and early clinical studies have suggested that various mRNA treatment platforms can induce cancer-specific cytolytic activity, leading to numerous clinical trials to determine the optimal method of combinations and sequencing with already established agents in cancer treatment. Nevertheless, further research is required to optimize RNA stabilization, delivery platforms, and improve clinical efficacy by interacting with the tumor microenvironment to induce a long-term antitumor response. This review provides a comprehensive summary of the available evidence on the recent advances and efforts to overcome existing challenges of mRNA-based treatment strategies, and how these efforts play key roles in offering perceptive insights into future considerations for clinical application.

1 June 2007 in Medical Oncology
Verified
Journal Article
Closed access
PDF file
HKHakan Karagol
Hakan Karagol
PSPinar Saip
Pinar Saip
KUKazim Uygun
Kazim Uygun
MCMurat Caloglu
Murat Caloglu
YEYesim Eralp
Yesim Eralp
ETErkan Topuz
Erkan Topuz

1 July 2003 in International Journal of Gynecological Cancer
Verified
Journal Article
Closed access
PDF file
YEYesim Eralp
Yesim Eralp
PSP. Saip
P. Saip
BSB. Sakar
B. Sakar
SKS. Kucucuk
S. Kucucuk
AAA. Aydiner
A. Aydiner
ETE. Topuz
E. Topuz